Scholarlink

Abstract <p>Chronic kidney disease (CKD) is a serious global public health concern, affecting around 13% of the population. Anemia represents a prevalent consequence of CKD. Anemia improves the probability of cardiovascular disease, accelerates the course of kidney failure, and reduces life quality. Patients with CKD can develop anemia for a variety of reasons, which include but are not limited to lack of renal function. These individuals need a thorough assessment to determine and treat causes of anemia besides erythropoietin insufficiency. However, there is evidence of a lack of circulating erythropoietin (EPO). In this study, we evaluated serum EPO levels in 41 severely anemic individuals with HGB below 7 g/dL, including 184 ESRD patients with and without hepatitis C. The ESRD group with severe anemia showed serum EPO levels of 1.3–1.7 pg/mL, whereas the ESRD group with HCV had an EPO level of 1.0–1.2 pg/mL. Consider using recombinant human erythropoietin (rHuEPO) to treat the condition.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anemia of Chronic Renal Failure and ESRD with Hepatitis C Patients: Role of Erythropoietin

  • 期刊论文

  • 发表日期：

    2025年9月1日

查看全文
  • Marwa Adnan Jabbar,
  • Jawad Kadhum Muraih

摘要

Abstract

Chronic kidney disease (CKD) is a serious global public health concern, affecting around 13% of the population. Anemia represents a prevalent consequence of CKD. Anemia improves the probability of cardiovascular disease, accelerates the course of kidney failure, and reduces life quality. Patients with CKD can develop anemia for a variety of reasons, which include but are not limited to lack of renal function. These individuals need a thorough assessment to determine and treat causes of anemia besides erythropoietin insufficiency. However, there is evidence of a lack of circulating erythropoietin (EPO). In this study, we evaluated serum EPO levels in 41 severely anemic individuals with HGB below 7 g/dL, including 184 ESRD patients with and without hepatitis C. The ESRD group with severe anemia showed serum EPO levels of 1.3–1.7 pg/mL, whereas the ESRD group with HCV had an EPO level of 1.0–1.2 pg/mL. Consider using recombinant human erythropoietin (rHuEPO) to treat the condition.